Dr. Leonardo Angelone is the Deputy Director for the Office of Translational Initiatives and Program Innovations at the National Institutes on Drug Abuse (NIDA). Prior to joining NIDA, Dr. Angelone was for over 9 years with the FDA Center for Devices and Radiological Health (CDRH), where he led a program that investigated the effects of electromagnetic energy generated by medical devices on the human body. He was principal investigator on multiple research projects, establishing and leading collaborations with government, industry, and academia. Dr. Angelone provides leadership for the vigorous pursuit of excellence in research translation and utilization of innovative programs to speed the application of research discoveries in the prevention, monitoring, diagnosis, and treatment of Substance Use Disorders. He serves as Program Lead of the new Trans-NIH Blueprint MedTech Program and as Program Officer of the NIDA small business innovation research (SBIR) and small business technology transfer (STTR) programs, with emphasis on Medical Devices and Digital Therapeutics. He also serves as Program Lead of the “RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19)” program, as part of the NIH Rapid Acceleration of Diagnostics (RADX) initiative, launched to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. Dr. Angelone has completed a Laurea (Doctor) in Electrical Engineering from University of Rome “Sapienza”, a Ph.D in Biomedical Engineering from Tufts University (Medford, MA), and a Research Fellowship from the Department of Radiology, Harvard Medical School.